Literature DB >> 385330

Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes.

J M Mencia-Huerta, J Benveniste.   

Abstract

Platelet-activating factor (PAF) is a phospholipid mediator of anaphylaxis, released from basophils of several mammalian species, that aggregates platelets and releases their vasoactive amines. The ionophore A23 187 induced the release of PAF from rat and mouse peritoneal cells, a mixed cell population that was fractionated using 5--15% Ficoll gradients and adherence to plastic petri dishes. PAF was associated with large, acid phosphatase-containing, adherent mononuclear cells. Mastocytes did not release PAF but released histamine by the action of ionophore or 48/80; they could not be held responsible for inactivation of PAF or inhibition of the PAF-induced platelet aggregation. These data indicate that, besides blood basophils, peritoneal macrophages are a likely source for PAF, a result that adds a new important function to the macrophage:aggregation of platelets and liberation of their inflammatory and vasoactive substances.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 385330     DOI: 10.1002/eji.1830090512

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  55 in total

1.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

2.  The role of platelet-activating factor and peptidoleukotrienes in the vascular changes of rat passive anaphylaxis.

Authors:  S Fernández-Gallardo; M A Gijón; C García; V Furio; F T Liu; M Sánchez Crespo
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration.

Authors:  J L Wallace; B J Whittle
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

4.  Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.

Authors:  T Yamada; M Saito; T Mase; H Hara; H Nagaoka; K Murase; K Tomioka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Gastrointestinal damage induced by platelet-activating factor. Inhibition by the corticoid, dexamethasone.

Authors:  J L Wallace; B J Whittle
Journal:  Dig Dis Sci       Date:  1988-02       Impact factor: 3.199

6.  Biosynthesis of paf-acether. Paf-acether but not leukotriene C4 production is impaired in cultured macrophages.

Authors:  A Dulioust; E Vivier; N Meslier; R Roubin; I Haye-Legrand; J Benveniste
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

7.  Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages.

Authors:  M Watanabe; M Yamada; S Mue; K Ohuchi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

8.  Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor.

Authors:  G Camussi; I Pawlowski; C Tetta; C Roffinello; M Alberton; J Brentjens; G Andres
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

9.  Platelet activating factor as a mediator of equine cell locomotion.

Authors:  J Dawson; P Lees; A D Sedgwick
Journal:  Vet Res Commun       Date:  1988       Impact factor: 2.459

Review 10.  Human IgE-independent systemic anaphylaxis.

Authors:  Fred D Finkelman; Marat V Khodoun; Richard Strait
Journal:  J Allergy Clin Immunol       Date:  2016-04-26       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.